Clinical trial • Phase I • Haematology
BGB-11417 for Mature B-cell malignancies
Phase I trial of BGB-11417 for Mature B-cell malignancies. None/Not specified-controlled. 368 participants.
Overview
- Trial Therapeutic Area
- Haematology
- Trial Disease
- Mature B-cell malignancies
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 30-09-2024
- First CTIS Authorization Date
- 10-10-2024
Trial design
None/Not specified-controlled Phase I trial across 14 sites in Italy, Spain.
- Comparator
- None/Not specified
- Target Sample Size
- 368
Eligibility
Recruits 368 Vulnerable population selected (isVulnerablePopulationSelected: true). No details on consent or assent handling provided in the record..
- Vulnerable Population
- Vulnerable population selected (isVulnerablePopulationSelected: true). No details on consent or assent handling provided in the record.
Recruitment
- Planned Sample Size
- 368
- Recruitment Window Months
- 92
Geography
- Total Number Of Sites
- 14
- Total Number Of Participants
- 69
Italy
- Earliest CTIS Part Ii Submission Date
- 27-08-2024
- Latest Decision Or Authorization Date
- 12-02-2026
- Processing Time Days
- 534
- Number Of Sites
- 6
- Number Of Participants
- 34
Sites
- Site Name
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Department Name
- U.O.C. Ematologia e Trapianto di cellule staminali emopoietiche
- Principal Investigator Name
- Luca Laurenti
- Principal Investigator Email
- luca.laurenti@unicatt.it
- Contact Person Name
- Luca Laurenti
- Contact Person Email
- luca.laurenti@unicatt.it
- Site Name
- Hospital Santa Maria Della Misericordia
- Department Name
- S.C. Ematologia e Trapianto
- Principal Investigator Name
- Paolo Sportoletti
- Principal Investigator Email
- laboratorio.sportoletti@ospedale.perugia.it
- Contact Person Name
- Paolo Sportoletti
- Contact Person Email
- laboratorio.sportoletti@ospedale.perugia.it
- Site Name
- Azienda Unita Sanitaria Locale Della Romagna
- Department Name
- U.O. di Ematologia
- Principal Investigator Name
- Monica Tani
- Principal Investigator Email
- monica.tani@auslromagna.it
- Contact Person Name
- Monica Tani
- Contact Person Email
- monica.tani@auslromagna.it
- Site Name
- ASST Grande Ospedale Metropolitano Niguarda
- Department Name
- Dipartimento Ematologia, Oncologia e Medicina Molecolare
- Principal Investigator Name
- Anna Maria Frustaci
- Principal Investigator Email
- annamaria.frustaci@ospedaleniguarda.it
- Contact Person Name
- Anna Maria Frustaci
- Contact Person Email
- annamaria.frustaci@ospedaleniguarda.it
- Site Name
- Ospedale San Raffaele S.r.l.
- Department Name
- U.O. Ematologia e Trapianto di Midollo Osseo
- Principal Investigator Name
- Paolo Ghia
- Principal Investigator Email
- ghia.paolo@hsr.it
- Contact Person Name
- Paolo Ghia
- Contact Person Email
- ghia.paolo@hsr.it
- Site Name
- Centro Ricerche Cliniche Di Verona S.r.l.
- Department Name
- U.O.C Ematologia
- Principal Investigator Name
- Andrea Bernardelli
- Principal Investigator Email
- andrea.bernardelli@aovr.veneto.it
- Contact Person Name
- Andrea Bernardelli
- Contact Person Email
- andrea.bernardelli@aovr.veneto.it
Spain
- Earliest CTIS Part Ii Submission Date
- 27-08-2024
- Latest Decision Or Authorization Date
- 12-02-2026
- Processing Time Days
- 534
- Number Of Sites
- 8
- Number Of Participants
- 35
Sites
- Site Name
- Hospital Clinic De Barcelona
- Department Name
- Hematology Department
- Principal Investigator Name
- LAURA MAGNANO
- Principal Investigator Email
- protecciodades@clinic.cat
- Contact Person Name
- LAURA MAGNANO
- Contact Person Email
- protecciodades@clinic.cat
- Site Name
- Institut Catala D'oncologia
- Department Name
- Hematology Department
- Principal Investigator Name
- EVA GONZALEZ BARCA
- Principal Investigator Email
- opd@iconcologia.net
- Contact Person Name
- EVA GONZALEZ BARCA
- Contact Person Email
- opd@iconcologia.net
- Site Name
- Vall D Hebron Institute Of Oncology
- Department Name
- Department of Hematology
- Principal Investigator Name
- FRANCESC BOSCH
- Principal Investigator Email
- dpd@ticsalutsocial.cat
- Contact Person Name
- FRANCESC BOSCH
- Contact Person Email
- dpd@ticsalutsocial.cat
- Site Name
- Clinica Universidad De Navarra
- Department Name
- Hematology department
- Principal Investigator Name
- MIGUEL CANALES
- Principal Investigator Email
- dpocun@unav.es
- Contact Person Name
- MIGUEL CANALES
- Contact Person Email
- dpocun@unav.es
- Site Name
- Hospital De La Santa Creu I Sant Pau
- Department Name
- Hematology Department
- Principal Investigator Name
- MIGUEL ARGÜELLO
- Principal Investigator Email
- dpd@santpau.cat
- Contact Person Name
- MIGUEL ARGÜELLO
- Contact Person Email
- dpd@santpau.cat
- Site Name
- Hospital Universitario Marques De Valdecilla
- Department Name
- Hematology unit
- Principal Investigator Name
- LUCRECIA YAÑEZ
- Principal Investigator Email
- alfonso.romano@scsalud.es
- Contact Person Name
- LUCRECIA YAÑEZ
- Contact Person Email
- alfonso.romano@scsalud.es
- Site Name
- Hospital Universitario De Salamanca
- Department Name
- Hematology
- Principal Investigator Name
- ALMUDENA NAVARRO
- Principal Investigator Email
- dpd@saludcastillayleon.es
- Contact Person Name
- ALMUDENA NAVARRO
- Contact Person Email
- dpd@saludcastillayleon.es
- Site Name
- Hospital Universitario Fundacion Jimenez Diaz
- Department Name
- Hematology
- Principal Investigator Name
- DANIEL MORILLO
- Principal Investigator Email
- dmorillo@startmadrid.com
- Contact Person Name
- DANIEL MORILLO
- Contact Person Email
- dmorillo@startmadrid.com
Sponsor
Primary sponsor
- Full Name
- BeOne Medicines AG
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Switzerland
Investigational products
- Investigational Product Name
- BGB-11417
Related trials
Other published trials that may interest you.
- (S)-4,5-DIHYDRO-2-[2-HYDROXY-4-(3,6-DIOXAHEPTYLOXY)PHENYL]-4-METHYL-4-THIAZOLECARBOXYLIC ACID for Transfusion-dependent alpha thalassemia | Transfusion-dependent beta thalassemia | Low-risk myelodysplastic syndromes
- Luspatercept for Myelofibrosis | Anemia associated with myeloproliferative neoplasm-associated myelofibrosis
- GIVINOSTAT for Chronic myeloproliferative neoplasm
- GOLCADOMIDE for Follicular lymphoma (advanced stage)
- ISATUXIMAB for Acute lymphoblastic leukaemia | T-lymphoblastic lymphoma